SCHEMBL4771931

SCHEMBL4771931

CCOC(=O)c1noc2cc[c]cc12

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MLYCD O95822 1/20 0.44
TDP2 O95551 2/20 0.42
ALDH1A1 P00352 5/20 0.41
HTT P42858 3/20 0.40
KDM4E B2RXH2 2/20 0.39
POLB P06746 2/20 0.38
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
MAPT P10636 1/20 0.38
PKM P14618 2/20 0.38
LMNA P02545 1/20 0.38
TARBP2 Q15633 1/20 0.37
CA12 O43570 1/20 0.37
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
CA7 P43166 1/20 0.37
CA9 Q16790 1/20 0.37
CA14 Q9ULX7 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4778042 0.89 TDP2 (0.42) MLYCDTDP2ALDH1A1HTTKDM4E
SCHEMBL30174438 0.80 KDM4E (0.52) ALDH1A1KDM4EPOLB
SCHEMBL1572943 0.80 KDM4E (0.52) ALDH1A1KDM4EPOLB
SCHEMBL17321037 0.77 MAPT (0.54) ALDH1A1KDM4EPOLBNPC1RAB9A
SCHEMBL31435418 0.77 MAPT (0.54) ALDH1A1KDM4EPOLBNPC1RAB9A
SCHEMBL25408093 0.75 MAOB (0.55) ALDH1A1KDM4ENPC1RAB9AMAPT
SCHEMBL31435424 0.75 MAOB (0.55) ALDH1A1KDM4ENPC1RAB9AMAPT
SCHEMBL1965601 0.75 ELANE (0.49) ALDH1A1KDM4EPOLBMAPTPKM
SCHEMBL13209975 0.75 THRB (0.51) MLYCDALDH1A1HTTKDM4ENPC1
SCHEMBL30440611 0.75 ELANE (0.49) ALDH1A1KDM4EPOLBMAPTPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1991530-A1 CINNOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS Amgen Inc. (US) 2008-11-19 EP claimed
US-20070265256-A1 Phosphodiesterase 10 inhibitors AMGEN INC. 2007-11-15 US claimed
WO-2007098169-A1 CINNOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS AMGEN INC. (US) 2007-08-30 WO claimed
EP-1991530-A1 CINNOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS Amgen Inc. (US) 2008-11-19 EP disclosed
US-20070265256-A1 Phosphodiesterase 10 inhibitors AMGEN INC. 2007-11-15 US disclosed
WO-2007098169-A1 CINNOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS AMGEN INC. (US) 2007-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070265256-A1 Phosphodiesterase 10 inhibitors PDE7A, PDE7B, PDE10A MLYCD 1143/4885TDP2 640/4885ALDH1A1 365/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.